Future prospects for luteinizing hormone-releasing hormone analogues in prostate cancer treatment.
about
The primary therapy chosen for patients with localized prostate cancer between the university hospital and its affiliated hospitals in Nara Uro-Oncological Research Group registration.Clinical pharmacology and regulatory consequences of GnRH analogues in prostate cancerTachykinin neurokinin 3 receptor antagonists: a patent review (2005 - 2010).A phase 2 study of abiraterone acetate in Japanese men with metastatic castration-resistant prostate cancer who had received docetaxel-based chemotherapy.Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapyPhase-1 study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancerRole of hormonal therapy for prostate cancer: perspective from Japanese experiences.Effectiveness and adverse effects of hormonal therapy for prostate cancer: Japanese experience and perspectiveEvaluation of primary androgen deprivation therapy in prostate cancer patients using the J-CAPRA risk score.The Use of Androgen Deprivation Therapy (ADT) and Chemotherapeutic Agents in New Zealand Men with Prostate Cancer.Is there an optimal management for localized prostate cancer?Current and future applications of GnRH, kisspeptin and neurokinin B analogues.Cardiovascular risk after androgen deprivation therapy for prostate cancer: an Asian perspective.Effects of radiation and total androgen blockade on serum hemoglobin, testosterone, and erythropoietin in patients with localized prostate cancer.A single-center study on predicting outcomes of primary androgen deprivation therapy for prostate cancer using the Japan Cancer of the Prostate Risk Assessment (J-CAPRA) score.Trans-Pacific variation in outcomes for men treated with primary androgen-deprivation therapy (ADT) for prostate cancer.Feasibility of metronomic chemotherapy with tegafur-uracil, cisplatin, and dexamethasone for docetaxel-refractory prostate cancer.Evidenced-based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition).
P2860
Q33882835-39E3E789-D6D2-45C7-85F2-71C62751649FQ34104391-7218EF35-1DA4-421D-85A2-A0BF205C6473Q34171734-D3FD599A-D581-4384-9C7E-0CED2891AF6AQ34569684-15666502-1517-4504-A047-8F3868AB128AQ35635497-5C55573B-35A4-4125-BC3D-2B0A47D8189AQ35713138-4363BE8E-1B47-44CC-9014-C38D8CFE1F8CQ36450795-121BC800-6ACB-4EC2-8598-ABBD9BA6C85CQ37044229-C97FCFFB-8A5B-4817-85D4-62717D1D26C8Q37270472-16027F58-DF98-40F3-87C6-4612C44FAB5FQ37596760-37736797-DA21-4026-8012-A6DD95D7C46BQ37780107-69A32554-D12C-4F1F-BD11-74CF92BC62DDQ38118569-A3F53F54-75A4-46E7-A56D-7B456B0DC82DQ38852165-B2CA1DFD-2D09-4117-86DE-6F70D8B1C30DQ42140990-2B3363A2-41C8-46F4-B93D-3B69B9D9A0D9Q44238565-6734A622-F702-45FF-B926-467E4C675758Q46772110-AF8B9F23-7413-44AE-BA4D-67BAE976F527Q47103953-648FFC90-4292-4C0F-B782-6DFF3E07EF4FQ53734447-A070B030-7804-4F10-A5CD-641346B7CB1F
P2860
Future prospects for luteinizing hormone-releasing hormone analogues in prostate cancer treatment.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 03 February 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Future prospects for luteinizi ...... in prostate cancer treatment.
@en
Future prospects for luteinizi ...... in prostate cancer treatment.
@nl
type
label
Future prospects for luteinizi ...... in prostate cancer treatment.
@en
Future prospects for luteinizi ...... in prostate cancer treatment.
@nl
prefLabel
Future prospects for luteinizi ...... in prostate cancer treatment.
@en
Future prospects for luteinizi ...... in prostate cancer treatment.
@nl
P356
P1433
P1476
Future prospects for luteinizi ...... in prostate cancer treatment.
@en
P2093
Hideyuki Akaza
P304
P356
10.1159/000274486
P577
2010-02-03T00:00:00Z